+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global CRISPR Technology Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 147 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5780635
The CRISPR technology market size attained a value of USD 1.8 billion in 2022. By 2031, The market is likely to grow at a rate of 23.1% during the forecast period of 2023-2031 to attain a value of USD 11.9 billion by 2031. The growth can be attributed to the increase in the mergers and acquisitions of strategic key players.

CRISPR Technology Market: Introduction

The global CRISPR technology market is a rapidly growing market driven by the increasing demand for efficient and precise gene editing tools, the growing funding for genomics research, and advancements in CRISPR technology. The market refers to the market for the clustered regularly interspaced short palindromic repeats (CRISPR) technology, which is a revolutionary gene editing tool used to alter the DNA sequence of an organism. The market is being propelled by factors such as the increasing prevalence of genetic disorders, the rise in the geriatric population, and the growth of the biotechnology and pharmaceutical industries.

CRISPR Technology Market- Application and Usage

CRISPR technology has a wide range of applications and usage in various fields, including:
1. Gene therapy: CRISPR technology is used to treat genetic diseases by correcting or replacing the defective genes in a patient's cells. This approach has shown promising results in treating diseases such as sickle cell anaemia and cystic fibrosis.
2. Genetic engineering: CRISPR technology is used to modify the genes of plants and animals to enhance their characteristics, such as increased yield or disease resistance.
3. Drug discovery: CRISPR technology is used to identify new drug targets and test the effectiveness of potential drugs.
4. Agricultural biotechnology: CRISPR technology is used to develop crops that are resistant to pests and diseases, have a longer shelf life, and have better nutritional value.
5. Cancer research: CRISPR technology is used to study the genes that play a role in the development and progression of cancer, which could lead to the development of new cancer treatments.
6. Infectious disease research: CRISPR technology is used to study the genes of pathogens and develop new treatments for infectious diseases.

Overall, CRISPR technology has the potential to revolutionize many fields, from medicine to agriculture, by providing a precise and efficient tool for gene editing and modification.

CRISPR Technology Market Segmentations

The market can be categorised into type, Cas type, application, and end user.

Market Breakup by Type

  • Cas9 and gRNA
  • Design Tools
  • Plasmid and Vectors
  • Other Delivery System Products

Market Breakup by Cas Type

  • Cas3 in Type I Systems
  • Cas9 in Type II Systems
  • Cas10 in Type III Systems

Market Breakup by Application

  • Genome Engineering
  • Disease Models
  • Functional Genomics
  • Knockdown/Activation
  • Others

Market Breakup by End User

  • Academic Research Organizations
  • Biopharmaceutical Companies
  • Agriculture Biotechnology Companies
  • Contract Research Organizations (CROs)

CRISPR Technology Market Breakup by Region

North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

CRISPR Technology Market Scenario

The global CRISPR technology market is expected to witness significant growth in the coming years. The market is being propelled by factors such as the increasing demand for efficient and precise gene editing tools, the growing funding for genomics research, and advancements in CRISPR technology. Moreover, the rise in the geriatric population, the increasing prevalence of genetic disorders, and the growth of the biotechnology and pharmaceutical industries are also driving the growth of the market.

North America is the dominant market for CRISPR technology, followed by Europe and the Asia Pacific. The high prevalence of genetic disorders, the presence of key players in the region, and the growing funding for genomics research are driving the growth of the market in North America and Europe. The Asia Pacific region is expected to witness the highest CAGR during the forecast period, owing to the growing demand for personalized medicine, the increasing prevalence of genetic disorders, and the rising healthcare expenditure in the region. Moreover, the growing investments in research and development activities and the presence of a large patient pool are expected to fuel the growth of the CRISPR technology market in the Asia Pacific region.

The CRISPR technology market is expected to face challenges such as ethical concerns surrounding gene editing and the high cost of CRISPR technology. However, the market is expected to present numerous growth opportunities such as the increasing demand for personalized medicine, the rising investments in research and development activities, and the growing adoption of CRISPR technology in developing countries.

Key Players in the Global CRISPR Technology Market

The report gives an in-depth analysis of the key players involved in the CRISPR Technology market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • Horizon Discovery Group plc
  • Sangamo Therapeutics
  • GenScript Biotech
  • Integrated DNA Technologies, Inc
  • Precision Biosciences
  • Beam Therapeutics Inc
  • Thermo Fisher Scientific Inc
  • Intellia Therapeutics
  • CRISPR Therapeutics AG
  • Vertex Pharmaceuticals Incorporated
  • New England Biolabs
  • Agilent Technologies, Inc
  • Merck KGaA
Frequently Asked Questions about the Global CRISPR Technology Market

What is the estimated value of the Global CRISPR Technology Market?

The Global CRISPR Technology Market was estimated to be valued at $2.21 Billion in 2023.

What is the growth rate of the Global CRISPR Technology Market?

The growth rate of the Global CRISPR Technology Market is 23.1%, with an estimated value of $11.9 Billion by 2031.

What is the forecasted size of the Global CRISPR Technology Market?

The Global CRISPR Technology Market is estimated to be worth $11.9 Billion by 2031.

Who are the key companies in the Global CRISPR Technology Market?

Key companies in the Global CRISPR Technology Market include Horizon Discovery Group plc, Sangamo Therapeutics, GenScript Biotech, Integrated DNA Technologies, Inc., Precision Biosciences, Beam Therapeutics Inc., Thermo Fisher Scientific Inc., Intellia Therapeutics, CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.1.1 Research Objectives
1.1.2 Key Findings of the Report
1.2 Limitations of the Study and Scope for Future Research
2 Research Methodology3 Executive Summary
4 Global CRISPR Technology Market
4.1 Global CRISPR Technology Market Overview
4.2 Global CRISPR Technology Market Analysis
4.2.1 Market Overview
4.2.1.1 Global CRISPR Technology Market Historical Value (2016-2022)
4.2.1.2 Global CRISPR Technology Market Forecast Value (2023-2031)
4.3 Global CRISPR Technology Market by Type
4.3.1 Market Overview
4.3.1.1 Cas9 and gRNA
4.3.1.2 Design Tools
4.3.1.3 Plasmid and Vectors
4.3.1.4 Other Delivery System Products
4.4 Global CRISPR Technology Market by Cas Type
4.4.1 Market Overview
4.4.1.1 Cas3 in Type I Systems
4.4.1.2 Cas9 in Type II Systems
4.4.1.3 Cas10 in Type III Systems
4.5 Global CRISPR Technology Market by Application
4.5.1 Market Overview
4.5.1.1 Genome Engineering
4.5.1.2 Disease Models
4.5.1.3 Functional Genomics
4.5.1.4 Knockdown/Activation
4.5.1.5 Others
4.6 Global CRISPR Technology Market by End User
4.6.1 Market Overview
4.6.1.1 Academic Research Organisations
4.6.1.2 Biopharmaceutical Companies
4.6.1.3 Agriculture Biotechnology Companies
4.6.1.4 Contract Research Organisations (CROs)
4.7 Global CRISPR Technology Market by Region
4.7.1 Market Overview
4.7.1.1 North America
4.7.1.1.1 Historical Trend (2016-2022)
4.7.1.1.2 Forecast Trend (2023-2031)
4.7.1.2 Europe
4.7.1.2.1 Historical Trend (2016-2022)
4.7.1.2.2 Forecast Trend (2023-2031)
4.7.1.3 Asia Pacific
4.7.1.3.1 Historical Trend (2016-2022)
4.7.1.3.2 Forecast Trend (2023-2031)
4.7.1.4 Latin America
4.7.1.4.1 Historical Trend (2016-2022)
4.7.1.4.2 Forecast Trend (2023-2031)
4.7.1.5 Middle East and Africa
4.7.1.5.1 Historical Trend (2016-2022)
4.7.1.5.2 Forecast Trend (2023-2031)
5 North America CRISPR Technology Market
5.1 United States of America
5.1.1 Historical Trend (2016-2022)
5.1.2 Forecast Trend (2023-2031)
5.2 Canada
5.2.1 Historical Trend (2016-2022)
5.2.2 Forecast Trend (2023-2031)
6 Europe CRISPR Technology Market
6.1 United Kingdom
6.1.1 Historical Trend (2016-2022)
6.1.2 Forecast Trend (2023-2031)
6.2 Germany
6.2.1 Historical Trend (2016-2022)
6.2.2 Forecast Trend (2023-2031)
6.3 France
6.3.1 Historical Trend (2016-2022)
6.3.2 Forecast Trend (2023-2031)
6.4 Italy
6.4.1 Historical Trend (2016-2022)
6.4.2 Forecast Trend (2023-2031)
7 Asia Pacific CRISPR Technology Market
7.1 China
7.1.1 Historical Trend (2016-2022)
7.1.2 Forecast Trend (2023-2031)
7.2 Japan
7.2.1 Historical Trend (2016-2022)
7.2.2 Forecast Trend (2023-2031)
7.3 India
7.3.1 Historical Trend (2016-2022)
7.3.2 Forecast Trend (2023-2031)
7.4 ASEAN
7.4.1 Historical Trend (2016-2022)
7.4.2 Forecast Trend (2023-2031)
7.5 Australia
7.5.1 Historical Trend (2016-2022)
7.5.2 Forecast Trend (2023-2031)
8 Latin America CRISPR Technology Market
8.1 Brazil
8.1.1 Historical Trend (2016-2022)
8.1.2 Forecast Trend (2023-2031)
8.2 Argentina
8.2.1 Historical Trend (2016-2022)
8.2.2 Forecast Trend (2023-2031)
8.3 Mexico
8.3.1 Historical Trend (2016-2022)
8.3.2 Forecast Trend (2023-2031)
9 Middle East and Africa CRISPR Technology Market
9.1 Saudi Arabia
9.1.1 Historical Trend (2016-2022)
9.1.2 Forecast Trend (2023-2031)
9.2 United Arab Emirates
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Nigeria
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
9.4 South Africa
9.4.1 Historical Trend (2016-2022)
9.4.2 Forecast Trend (2023-2031)
10 Trade Data Analysis by HS Code
10.1 Geneart CRISPR Nuclease Mrna- 38220090
10.2 Csq33 DNA Sequencing Unit- 90272000
11 Current Scenario Evaluation and Regulatory Framework
11.1 Emerging Therapies and Clinical Trials Synopsis
11.2 Patent Landscape
11.2.1 Patent Overview
11.2.1.1 Patent Status and Expiry
11.2.1.2 Timelines from Device Development to Commercial Launch
11.2.1.3 New Device Application
11.2.1.3.1 Documentation and Approval Process
11.3 Cost of Treatment
11.4 Regulatory Framework
11.4.1 Regulatory Overview
11.4.1.1 US FDA
11.4.1.2 EU EMA
11.4.1.3 INDIA CDSCO
11.4.1.4 JAPAN PMDA
11.4.1.5 Others
12 Global CRISPR Technology Market Dynamics
12.1 Market Drivers and Constraints
12.2 SWOT Analysis
12.3 Porter’s Five Forces Model
12.4 Key Demand Indicators
12.5 Key Price Indicators
12.6 Industry Events, Initiatives, and Trends
12.7 Value Chain Analysis
13 Supplier Landscape
13.1 Horizon Discovery Group plc
13.1.1 Company Overview
13.1.2 Product Portfolio
13.1.3 Demographic Reach and Achievements
13.1.4 Mergers and Acquisitions
13.1.5 Certifications
13.2 Sangamo Therapeutics
13.2.1 Company Overview
13.2.2 Product Portfolio
13.2.3 Demographic Reach and Achievements
13.2.4 Mergers and Acquisitions
13.2.5 Certifications
13.3 GenScript Biotech
13.3.1 Company Overview
13.3.2 Product Portfolio
13.3.3 Demographic Reach and Achievements
13.3.4 Mergers and Acquisitions
13.3.5 Certifications
13.4 Integrated DNA Technologies, Inc.
13.4.1 Company Overview
13.4.2 Product Portfolio
13.4.3 Demographic Reach and Achievements
13.4.4 Mergers and Acquisitions
13.4.5 Certifications
13.5 Precision Biosciences
13.5.1 Company Overview
13.5.2 Product Portfolio
13.5.3 Demographic Reach and Achievements
13.5.4 Mergers and Acquisitions
13.5.5 Certifications
13.6 Beam Therapeutics Inc.
13.6.1 Company Overview
13.6.2 Product Portfolio
13.6.3 Demographic Reach and Achievements
13.6.4 Mergers and Acquisitions
13.6.5 Certifications
13.7 Thermo Fisher Scientific Inc.
13.7.1 Company Overview
13.7.2 Product Portfolio
13.7.3 Demographic Reach and Achievements
13.7.4 Mergers and Acquisitions
13.7.5 Certifications
13.8 Intellia Therapeutics
13.8.1 Company Overview
13.8.2 Product Portfolio
13.8.3 Demographic Reach and Achievements
13.8.4 Mergers and Acquisitions
13.8.5 Certifications
13.9 CRISPR Therapeutics AG
13.9.1 Company Overview
13.9.2 Product Portfolio
13.9.3 Demographic Reach and Achievements
13.9.4 Mergers and Acquisitions
13.9.5 Certifications
13.10 Vertex Pharmaceuticals Incorporated
13.10.1 Company Overview
13.10.2 Product Portfolio
13.10.3 Demographic Reach and Achievements
13.10.4 Mergers and Acquisitions
13.10.5 Certifications
13.11 New England Biolabs
13.11.1 Company Overview
13.11.2 Product Portfolio
13.11.3 Demographic Reach and Achievements
13.11.4 Mergers and Acquisitions
13.11.5 Certifications
13.12 Agilent Technologies, Inc.
13.12.1 Company Overview
13.12.2 Product Portfolio
13.12.3 Demographic Reach and Achievements
13.12.4 Mergers and Acquisitions
13.12.5 Certifications
13.13 Merck KGaA
13.13.1 Company Overview
13.13.2 Product Portfolio
13.13.3 Demographic Reach and Achievements
13.13.4 Mergers and Acquisitions
13.13.5 Certifications
14 Recommendations and Discussion
15 Pricing Models and Strategies (Additional Insight)
15.1 Cost Model
15.1.1 Manufacturing Cost Analysis
15.1.2 Procurement Cost Analysis
15.1.3 Clinical Trial Cost Factors
15.2 Pricing Strategies
15.2.1 Competitor Pricing Analysis
15.2.2 Key Assessment of Product Attributes
15.2.3 Pricing Benchmark
16 Global CRISPR Technology Devices Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment

Companies Mentioned

  • Horizon Discovery Group plc
  • Sangamo Therapeutics
  • GenScript Biotech
  • Integrated DNA Technologies, Inc.
  • Precision Biosciences
  • Beam Therapeutics Inc.
  • Thermo Fisher Scientific Inc.
  • Intellia Therapeutics
  • CRISPR Therapeutics AG
  • Vertex Pharmaceuticals Incorporated
  • New England Biolabs
  • Agilent Technologies, Inc.
  • Merck KGaA

Methodology

Loading
LOADING...